Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

APEL Appoints Senior Director

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Appointment of Dr Susan Wood as Senior Director, Market Access.

Astellas Pharma Europe Ltd. (APEL) has appointed Dr Susan Wood as Senior Director, Market Access for Astellas Pharma Europe Ltd (APEL).

Formerly Senior Brand Director of APEL’s Pain Management franchise, she will now drive the Company’s market access activities with the aim of establishing its leadership in an area of ever increasing importance, in the face of current economic challenges.

She will report directly to Kay Drake, Vice President Marketing, Astellas Pharma Europe Ltd.

Welcoming Susan Wood to her new role, Ken Jones, President and CEO, Astellas Pharma Europe Ltd, said: “Astellas has proved time and again in recent years that it remains entirely possible to introduce effective new medicines that deliver value for payers - and that health services across Europe are willing to fund. Sue will be working closely with our Affiliates to drive the market access strategy across the Astellas Europe organization in our key therapeutic areas, focusing on developing evidence-based models from the early stages of R&D until the mature stages of the product lifecycle.”

Over the past three years, Susan Wood led the launch of QUTENZA™, an innovative treatment for peripheral neuropathic pain.

The successful introduction of QUTENZA has confirmed the value of integrating market access expertise at an early stage of strategic planning, and has also profiled Dr Wood’s abilities as a leader.

Commenting on her appointment, Susan Wood said: “Astellas Pharma Europe has recently launched its Oncology franchise, we are expecting some 11 products to be in launch or early-growth phase in the next three years. We are growing fast in Anti-Infectives, with the recently launched anti-infective DIFICLIR™, the first new treatment in 50 years for clostridium difficile (C.diff), and we continue to affirm our category leadership in Transplantation and Urology. I am very much looking forward to the challenge of supporting the company to achieve its strategic objectives.”

Susan Wood joined Astellas Pharma Europe Ltd in 2008 and has over 13 years’ experience in international pharmaceutical marketing, with a particular focus on launch strategies.

She previously held roles with Hoffmann-La Roche in Basel, Biogen in Paris and Sanofi Pasteur in Lyon. Before entering the pharmaceutical industry, she worked in clinical research.

Her academic background lies in neuroscience, with studies at both Oxford University and Harvard Medical School, and she has a PhD in Biochemistry, specializing in general anaesthesia.

Before entering the pharmaceutical industry she was also assistant editor of an international neuroscience journal.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!